Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Comparison of different dosage nebulised budesonide in COPD exacerbation Source: Annual Congress 2012 - COPD exacerbation Year: 2012
A comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a double-blind, efficacy and safety study in Chinese adults with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Efficacy of nebulized arformoterol, a long-acting β2 -adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010
Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
High doses inhaled salbutamol by MDI in patients with acute bronchial asthma and its cardiopulmonary effects Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 14s Year: 2005
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004